504
Views
0
CrossRef citations to date
0
Altmetric
Editorial

IgG-VHH bispecific fusion antibodies: challenges and opportunities as therapeutic agents

ORCID Icon, ORCID Icon & ORCID Icon
Pages 203-206 | Received 05 Feb 2024, Accepted 25 Mar 2024, Published online: 27 Mar 2024
 

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This work was supported by The Novo Nordisk Foundation Grant NNF19SA0056783, NNF19SA0057794, and NNF20SA0066621.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.